Clinical trial
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim…
NCT00026312 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00026312 |
|---|---|
| Title | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma |
| Official title | Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma |
| Intervention type | Biological, Drug, Other |
| Interventions | Aldesleukin, Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Sargramostim |
| Enrollment | 1,449 |
| Start date | Oct 18, 2001 |
| Primary completion | Jan 12, 2012 |
| Completion | Mar 19, 2026 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 24, 2025 |
| Countries | Australia, Canada, New Zealand, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: